New interactions reported for Strattera

The Summary of Product Characteristics for the ADHD treatment Strattera (atomoxetine) has been updated to warn of the possible risk of QT prolongation if the drug is used with other drugs that prolong the QT interval, cause electrolyte disturbances or inhibit CYP2D6.

Also, because of the risk of seizures, caution should be exercised with the concomitant use of drugs known to lower the seizure threshold.

Further information: Lilly, Lilly House, Priestley Road, Basingstoke, Hants RG24 9NL. Tel: (01256) 315000.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more